about
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain managementIrinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study.A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.Systemic chemotherapy in elderly patients with locally advanced and/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and role of recombinant human erythropoietin.Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials.Oral versus intravenous vinorelbine: clinical safety profile.Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?Cetuximab in squamous cell head and neck carcinomas.Cetuximab: clinical results in colorectal cancer.Adjuvant therapy in colon cancer.Anticancer oral therapy: emerging related issues.Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.New opioids.Cancer pain management in an oncological ward in a comprehensive cancer center with an established palliative care unit.Does pain intensity predict a poor opioid response in cancer patients?Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study.Breakthrough pain in oncology: a longitudinal study.Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients.Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.First-line treatment with epirubicin and vinorelbine in metastatic breast cancer.Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen.A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
P50
Q27851712-1EA1B15F-8D33-4623-A69C-75F7CADFAB5EQ28273281-8312599D-9152-4E08-8F4E-11590957350FQ33228157-FBE05D27-C4F5-4591-AA69-9488AC24A146Q33332763-7919A7EA-5FAD-4D74-BE3F-8C4254FC20BDQ33341559-6C3435BF-7C3F-4EC6-B6D0-02BA8011BD09Q33343371-46D5A20A-7C89-4DA8-9760-610157FBA413Q33343836-57C5D67E-3DB8-4E1D-B888-9A71D1989361Q33366660-FB5E4147-4AD4-4D8F-BEDF-2378487C830BQ33371478-2AD604A1-63CC-4152-821E-9227A9CF773DQ33372127-279BFC0C-CE83-4C7D-8DF2-9E866F5B974DQ33395752-6948FB00-8AED-451A-83ED-ED98B6D7D78DQ33397990-6E061B5B-326D-4C27-B440-90820235748CQ33409103-A1CDBE31-AC37-4D40-9274-D15D346CC857Q33497773-055E3807-9BC0-4FE4-A3D8-6E89DB1BAFBAQ33521596-E6CC273D-BF9A-45A0-8C0C-718DFB8E0F59Q33996606-2F182CEB-1F65-40F6-9657-98B9D3171D89Q34617300-63CA7EFC-FF81-493B-A529-0483CF5B72E6Q35561762-FD9CDD7B-F5DB-4922-A3D0-731E80991575Q36143655-769458A0-2923-44CA-A794-BE5BBCB28A1DQ36143659-C79BAF61-5EAF-449F-88ED-6478E02AE49AQ36235526-EEC25991-7BA3-4049-BCAB-5D01F75E8A43Q36243741-4527BE75-3FBC-48F2-9F7F-D2E155315300Q36445885-74E50B9B-55BB-49AE-B12E-3D80E6F59B9DQ36860202-446DA127-38AE-4470-B23E-EB41EA6FC043Q36860229-476DD9BE-C2F5-4642-8E0E-E67F2374C9EDQ37687022-CF4F7B11-80FE-4339-9E93-439EF2C870C6Q37767033-6D1E0C0A-DC62-42C8-8745-91E35A67A20FQ37965653-255F3490-C618-4D6C-96BD-16EFF2252F66Q38209633-D800F487-18B5-47A9-AD8B-2579CC433B60Q39223223-54E74729-1A91-44A7-A42A-73B6DA4FF90BQ39272665-EA477EF3-7E0F-4649-9D0F-5E83A69C7328Q39278044-1AF56240-8283-4927-BAE8-ADD33C3EDD21Q39286368-228D3FEA-B26D-43F1-A6FA-D76C36361F06Q39307343-BF5E7912-1E29-4F59-B4C0-E7D16985C552Q39986130-92665DA9-659B-4AE3-878C-23E630AF9B27Q40581449-3F7568B3-98BB-4FA4-9AB8-9A45CD8384F4Q40693607-574E33B3-A762-4B32-AE16-2E1DD15A94A2Q41652822-DF7F9D15-68FD-424B-9259-BE37C271C5E0Q43168112-0A22EDBC-2E54-474C-A7A8-E1B11B08954FQ43526971-1E8F2C46-54C7-4848-81A9-095D87F276F2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vittorio Gebbia
@ast
Vittorio Gebbia
@en
Vittorio Gebbia
@es
Vittorio Gebbia
@nl
Vittorio Gebbia
@sl
type
label
Vittorio Gebbia
@ast
Vittorio Gebbia
@en
Vittorio Gebbia
@es
Vittorio Gebbia
@nl
Vittorio Gebbia
@sl
prefLabel
Vittorio Gebbia
@ast
Vittorio Gebbia
@en
Vittorio Gebbia
@es
Vittorio Gebbia
@nl
Vittorio Gebbia
@sl
P106
P1153
35478767500
P21
P31
P496
0000-0001-8848-5951
P569
2000-01-01T00:00:00Z